Clare C. Sun

Hematology

136 Mountainview Blvd
Basking Ridge, NJ 07920

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.

Sudden death and asymptomatic arrhythmia in chronic lymphocytic leukemia patients treated with ibrutinib.

Journal: Heart rhythm

Published: July 02, 2025

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study.

Journal: Blood

Published: June 06, 2025

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

A decade of ibrutinib for CLL with and without TP53 aberration: final report on an investigator-sponsored phase 2 study.

Journal: Blood

Published: June 06, 2025

Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell data.

Numbat-multiome: inferring copy number variations by combining RNA and chromatin accessibility information from single-cell data.

Journal: Briefings in bioinformatics

Published: June 04, 2025

Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.

Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: March 20, 2025

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.

Journal: Leukemia & lymphoma

Published: February 20, 2025

Preventing infectious complications in chronic lymphocytic leukemia.

Preventing infectious complications in chronic lymphocytic leukemia.

Journal: Clinical advances in hematology & oncology : H&O

Published: December 01, 2023

Vaccinations in patients with chronic lymphocytic leukemia.

Vaccinations in patients with chronic lymphocytic leukemia.

Journal: Seminars in hematology

Published: November 17, 2023

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.

Interruption of BTK inhibitor improves response to SARS-CoV-2 booster vaccination in patients with CLL.

Journal: Leukemia & lymphoma

Published: September 21, 2023

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia.

Journal: Blood

Published: July 31, 2023

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting.

Journal: Blood advances

Published: December 09, 2022

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.

CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression-Free Survival on BTK Inhibitor Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 22, 2022

Showing 1-12 of 56

Last Updated: 09/26/2026